Pharmaceutical firm Shire has reported a 20% rise in third-quarter earnings, beating market expectations, driven by growth in its immunology franchise.
The company posted non-GAAP earnings per share, its preferred measure, of $3.81 on total revenue of $3.70 billion.
It also reiterated its guidance for the year.
Analysts on average expected the company to report earnings per share of $3.69 on revenue of $3.75 billion for the third quarter.
